Zoe June F. Assaf
Genentech · 104 works · 4,696 citations · h-index 25
Top works
- Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer
- ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
- Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma
- Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
- ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
- Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
- Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma
- A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer
- Molecular determinants of response to PD-L1 blockade across tumor types
- Pairing Centers Recruit a Polo-like Kinase to Orchestrate Meiotic Chromosome Dynamics in C. elegans
- Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant (adj) atezolizumab (atezo) vs placebo (pbo) in patients (pts) with renal cell carcinoma (RCC) at increased risk of recurrence after resection.
- An actin cytoskeleton with evolutionarily conserved functions in the absence of canonical actin-binding proteins
- Circulating kidney injury molecule-1 (KIM-1) and association with outcome to adjuvant immunotherapy in renal cell carcinoma
- Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic NSCLC: Initial Results of the Phase 2 ALK-Positive Cohort
- 1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
- Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
- The population genetics of drug resistance evolution in natural populations of viral, bacterial and eukaryotic pathogens
- Naegleria gruberi De Novo Basal Body Assembly Occurs via Stepwise Incorporation of Conserved Proteins
- Nuclear Inheritance and Genetic Exchange without Meiosis in the Binucleate ParasiteGiardia intestinalis